Show simple item record

dc.contributor.authorMacFarlane, I A
dc.contributor.authorDavies, D
dc.contributor.authorLongson, D
dc.contributor.authorShalet, Stephen M
dc.contributor.authorBeardwell, Colin G
dc.date.accessioned2014-12-22T15:52:55Z
dc.date.available2014-12-22T15:52:55Z
dc.date.issued1983-06
dc.identifier.citationSingle daily dose short term carbimazole therapy for hyperthyroid Graves' disease. 1983, 18 (6):557-61 Clin Endocrinolen
dc.identifier.issn0300-0664
dc.identifier.pmid6411390
dc.identifier.urihttp://hdl.handle.net/10541/337552
dc.description.abstractTwenty-one patients with hyperthyroid Graves' disease were treated with carbimazole 30 mg daily, given as a single dose. Propranolol was also given for the first 3 weeks. All became clinically euthyroid with normal serum thyroxine (T4) levels, usually within 1-3 months. Patients with large goitres and raised serum alkaline phosphatase concentrations took longer to respond. In 19 patients a positive thyroid stimulating hormone (TSH) response to intravenous thyrotrophin releasing hormone (TRH) developed. Carbimazole was stopped soon after (median time of treatment 18 weeks, range 9-41 weeks) and 18 patients have been followed. Seven of these (39%) have remained in remission from hyperthyroidism for more than one year (median 77 weeks). Carbimazole 30 mg once daily is a convenient and effective treatment for hyperthyroid Graves' disease. Many patients will achieve prolonged remissions if treatment is stopped when serum T3 and T4 levels are in the low-normal range, usually 2-4 months after clinical euthyroidism has been reached.
dc.language.isoenen
dc.rightsArchived with thanks to Clinical endocrinologyen
dc.subject.meshAdult
dc.subject.meshCarbimazole
dc.subject.meshDrug Administration Schedule
dc.subject.meshDrug Therapy, Combination
dc.subject.meshFemale
dc.subject.meshGraves Disease
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPropranolol
dc.subject.meshThyrotropin
dc.subject.meshThyrotropin-Releasing Hormone
dc.subject.meshThyroxine
dc.subject.meshTriiodothyronine
dc.titleSingle daily dose short term carbimazole therapy for hyperthyroid Graves' disease.en
dc.typeArticleen
dc.contributor.departmentThe Christie Hospital, Manchesteren
dc.identifier.journalClinical Endocrinologyen
html.description.abstractTwenty-one patients with hyperthyroid Graves' disease were treated with carbimazole 30 mg daily, given as a single dose. Propranolol was also given for the first 3 weeks. All became clinically euthyroid with normal serum thyroxine (T4) levels, usually within 1-3 months. Patients with large goitres and raised serum alkaline phosphatase concentrations took longer to respond. In 19 patients a positive thyroid stimulating hormone (TSH) response to intravenous thyrotrophin releasing hormone (TRH) developed. Carbimazole was stopped soon after (median time of treatment 18 weeks, range 9-41 weeks) and 18 patients have been followed. Seven of these (39%) have remained in remission from hyperthyroidism for more than one year (median 77 weeks). Carbimazole 30 mg once daily is a convenient and effective treatment for hyperthyroid Graves' disease. Many patients will achieve prolonged remissions if treatment is stopped when serum T3 and T4 levels are in the low-normal range, usually 2-4 months after clinical euthyroidism has been reached.


This item appears in the following Collection(s)

Show simple item record